Washington Legal Foundation Advocate for Freedom and Justice ® WLF Balancing the Public's Right to Know With the Government's Obligation to Protect Patients.

Slides:

Advertisements

Similar presentations

The Regulation of Tobacco Advertising After Lorillard v. Reilly Michael F. Strande, J.D. Legal Resource Center for Tobacco Regulation, Litigation & Advocacy.

Advertisements

2010 UBO/UBU Conference Health Budgets & Financial Policy Briefing:Medical Affirmative Claims Date:24 March 2010 Time:1110 – 1200.

First Amendment Protection of Commercial Speech Vices and Tupperware.

© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.

1 Ch. 3. Advertising and Society. 2 Advertising’s Legal and Regulatory Environment.

Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.

25-1 Chapter 44 Consumer Protection and Product Safety.

RAC Study Group Chapter 16

FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.

May 13, 2005 North Carolina State University Off-Label Use and Product Liability: Basic Principles David L. Baumer, Ph.D., J.D., Attorney at Law, Professor.

An overview of off-label drug use Ignoring the Label Samantha Rue.

Consumer Protection Agencies Introduction to Business & Marketing.

November, 2004 Slide 1 FDA PROMOTIONAL RULES The Fifth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Arthur N. Levine.

Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Argentina v. Holdout Creditors: Applying the Rule of Law To Resolve Debt Default Richard.

1 Speech that FDA Regulates William A. McConagha Office of Accountability Food & Drug Administration Risk Communication Advisory Committee February 28,

Regulation of Drug Marketing Introduction to Drug Law and Regulation FDLI Workshop April 28-29, 2003 Teaneck, New Jersey Philip Katz Crowell & Moring LLP.

August, 2005 Slide 1 MANAGING RISKS OF OFF-LABEL PROMOTION AND CONTINUING MEDICAL EDUCATION The FDA Regulatory and Compliance Symposium Annenberg Hall.

The Regulatory Authority for Off-Label Promotion

Off Label Promotion of Medical Devices presented by Bradley Merrill Thompson Epstein Becker & Green P.C. June 21, 2006.

Copyright © 2005 Thomson Delmar Learning. ALL RIGHTS RESERVED.1 This product was funded by a grant awarded under the President’s Community-Based Job Training.

Privacy, Confidentiality and Duty to Warn in School Guidance Services March 2006 Disclaimer - While the information in these slides are designed to reflect.

HHS Office of the General Counsel

20__ Fredrikson & Byron P.A A Practical Path -- Does the First Amendment Matter? Presented by Bob Klepinski

The First Amendment and Restricting Food Marketing to Children AcademyHealth Washington DC, June 2008 Jennifer L. Pomeranz, JD,

Constitutional Law Part 8: First Amendment: Freedom of Expression Lecture 3: Places Available for Speech.

When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.

Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.

Overview of FDA's Regulatory Compliance Agenda Daniel Meron, Esq. General Counsel Department of Health and Human Services August 22, 2007.

Latham & Watkins operates as a limited liability partnership worldwide with affiliated limited liability partnerships conducting the practice in the United.

KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.

Can the First Amendment Save Controversial Packaging? Janet M. Evans Federal Trade Commission Presentation for NABCA Legal Symposium March 12, 2013.

Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.

FleetBoston Financial HIPAA Privacy Compliance Agnes Bundy Scanlan Managing Director and Chief Privacy Officer FleetBoston Financial.

© 2009 McGraw-Hill Higher Education. All rights reserved. Drug Products and Their Regulations.

© 2009 McGraw-Hill Higher Education. All rights reserved. Drug Products and Their Regulations.

Chapter 38 Consumer Law. 2  When will advertising be deemed deceptive?  How does the federal Food, Drug and Cosmetic Act protect consumers?  When will.

Making false claims about medicines - selling, advertising Enforcing the law Fatima Hassan Senior Attorney 26 September 2006.

Mass Media Law 18 th Edition Don Pember Clay Calvert Chapter 15 Regulation of Advertising McGraw-Hill/Irwin © 2013 McGraw-Hill Companies. All Rights Reserved.

© 2010 Pearson Education, Inc., publishing as Prentice-Hall 1 CONSUMER PROTECTION AND PRODUCT SAFETY © 2010 Pearson Education, Inc., publishing as Prentice-Hall.

Investigational Devices and Humanitarian Use Devices June 2007.

1 Complying with FDA/OIG Rules Wayne L. Pines August 24, 2006.

National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.

©2007 Fredrikson & Byron P.A. Presented by

Limitations and constraints

Flowers Hospital General Compliance Training-Students 2013.

FDA, Labeling, and Marketing

Public Communications Law Lecture 9 Slide 1 Commercial Speech and the First Amendment Commercial speech (advertising products, etc.) does enjoy certain.

Special Concerns Relating To Promotional Labeling And Advertising For Medical Devices.

Promotion of Prescription Drugs and Biologics Thomas O. Henteleff Kleinfeld, Kaplan and Becker LLP Company logo here.

© 2007 Prentice Hall, Business Law, sixth edition, Henry R. Cheeseman Consumer Protection.

BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Reprints.

Miller Cross 4 th Ed. © 2005 by West Legal Studies in Business / A Division of Thomson Learning Chapter 19 Consumer Protection.

Given the progress that continues to be made in society’s battle against disease, patients are seeking more information about medical problems and potential.

The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.

Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur.

Chapter 4 The Legal and Regulatory Environment of Health Care.

Action Items: Monitoring Off-Label Promotion Do’s and Don’t’s

Chapter 24 Economic, Social, and Legal Effects of Advertising

Ifdhal Kasim Human Rights Advocate

US Early Feasibility Studies (EFS)

FCA Enforcement: United States Department of Justice

Off-Label Liability: Legal and Compliance Issues

Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958

Generic Medical Device Company (“MDC”)

Opening an IND: Investigator Perspective

Compliance and Enforcement of the Privacy Rule

The Zyprexa and Bextra Settlements

Difficult to prevent reuse of single use devices

Regulatory Perspective of the Use of EHRs in RCTs

Presentation transcript:

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Balancing the Public's Right to Know With the Government's Obligation to Protect Patients Richard Samp Chief Counsel Washington Legal Foundation March 30, 2006

Washington Legal Foundation Advocate for Freedom and Justice ® WLF First Amendment Protection of Commercial Speech Four-Part Central Hudson Test: Inherently false or misleading / promotes an illegal activity Substantial government interest Directly promotes that interest Narrowly drawn

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Major Commercial Speech Decisions Regarding Medical Products Washington Legal Foundation v. Friedman (manufacturer dissemination of off-label information) Pierson v. Shalala (health claims for dietary supplements) Thompson v. Western States (pharmacists advertising compounding capabilities)

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Central Hudson - First Prong (Inherently False or Misleading) FDA has lost this issue Information is not "false" simply because FDA has not verified FDA "exaggerates the importance of its place in the universe"

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Central Hudson - Second Prong (Substantial Government Interest) Preventing potentially misleading speech (this rarely justifies speech bans; at most justifies disclaimers) Preventing Unnecessary Medical Treatment, thereby reducing costs (this interest was rejected by Western States) Encouraging manufacturers to seek labeling authority (this interest has generally been recognized as substantial)

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Central Hudson - Third Prong (Directly Promoting Government Interest) Government May Not Impose Speech Regulations That Don't Directly Advance Its Stated Interest If Government Justifies Its Policy by Pointing to Interest in Encouraging Mfrs to Seek Labeling Authority, It Must Show that the Policy Is Likely to Encourage Such Conduct

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Central Hudson - Fourth Prong (Narrowly Drawn) Can Government Achieve Its Policy Goals without Regulating Speech? Can It Do So With Regulations Short of a Speech Ban (e.g., Disclaimers)?

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Regulating Speech by Subterfuge This is Current Government Policy FDA Claims to Regulate Conduct, Not Speech Off-Label Speech Is Cited as Evidence of: - Intent to Market for Unapproved New Use - Product is Adulterated Because Not Labeled for Intended Use

Washington Legal Foundation Advocate for Freedom and Justice ® WLF What Is Off-Label Speech? Rarely Involves Speech Regarding Treatment of a Different Condition Much More Common: - Use at a Different Dosage - Use in Pediatric Populations - Comparative Claims

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Recent Enforcement Activity False Claims Act - Imposes liability on anyone who "knowingly presents or causes to be presented" a "false or fraudulent claim for payment of approval" to U.S. Anti-Kickback Statute - Prohibits payments to induce another to buy an item for which payment may be made under a federal health care program

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Targets of Enforcement Continuing Medical Education Advertising Distribution of Studies Consultation Payments to Doctors

Washington Legal Foundation Advocate for Freedom and Justice ® WLF What's Going on Here? Most investigations are run out of Boston or Philadelphia US Atty offices Others want in on the action -- this is a real moneymaker FDA has little control Coordination is done by Office of Consumer Litigation at DOJ's Civil Div. - Little sensitivity to off-label issues - WLF correspondence

Washington Legal Foundation Advocate for Freedom and Justice ® WLF Why Off-Label Speech Lives Are Lost When Helpful Information Is Suppressed FTC Approach -- Substantial Support FDA Permits Responses to Unsolicited Requests for Information FDA Often Prohibits All Studies Not Deemed "Well- controlled"